Peripheral Blood Stem Cell Isolation Without Feeder Layers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell research faces challenges such as ethical concerns and immune rejection, and there is a need for better methods to isolate autologous stem cells with embryonic-stem cell characteristics from readily available adult sources.
Innovation Solution
The method involves extracting peripheral blood mononuclear cells (PBMCs) from adult human peripheral blood, culturing them in a growth medium like RPMI 1640 with fetal bovine serum, and isolating embryonic-like stem cells using techniques that include positive selection markers like Oct-4, Nanog, and CD45, and negative selection markers like CD3 and CD14, without the need for feeder cell layers, to obtain a homogeneous population of stem cells capable of differentiation into various cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If embryonic stem cells are used for regenerative medicine, then therapeutic potential is improved, but ethical concerns and immune rejection increase
Solution Approach 1:
The patent creates a copy of embryonic stem cell properties in adult peripheral blood cells. By culturing adult PBMCs under specific conditions (RPMI 1640 medium with 10% FBS, no feeder cells), the cells acquire embryonic-like characteristics including expression of Oct-4, Nanog, and Sox-2 markers, while maintaining autologous identity to avoid immune rejection
Solution Approach 2:
The patent changes the physiological state parameters of adult peripheral blood cells through controlled culture conditions. By adjusting medium composition, serum concentration, and culture duration, the cells transition from mature PBMC phenotype to embryonic-like stem cell phenotype, expressing pluripotency markers while retaining donor-specificity
2Ease of operation
If stem cells are isolated from adult peripheral blood, then availability and ease of access are improved, but cell scarcity and isolation difficulty increase
Solution Approach 1:
The patent performs preliminary enrichment of stem cell progenitors in adult peripheral blood before final isolation. By pre-culturing PBMCs in RPMI 1640 with 10% FBS for 7-14 days, the cells undergo self-organization and differentiation into organized stem cell colonies that can be easily isolated using standard techniques like PAS staining and manual picking
Solution Approach 2:
The adult PBMCs perform self-organization and self-renewal during culture, spontaneously forming embryonic-like stem cell colonies without requiring external feeder cells or complex support structures. This self-service capability simplifies the isolation process while maintaining cell pluripotency
3Reliability
If feeder cell layers are used for stem cell culture, then cell growth and maintenance are improved, but device complexity and contamination risk increase
Solution Approach 1:
The patent extracts and eliminates the feeder cell layer from the stem cell culture system. By using defined media (RPMI 1640 with 10% FBS) and growth factors (bFGF, SCF, TPO) directly in the culture medium, the cells maintain growth and differentiation potential without requiring external feeder cells, thereby simplifying the culture system and reducing contamination risks
Solution Approach 2:
The patent creates a universal culture system that can maintain stem cell properties without feeder cells. The RPMI 1640 medium with 10% FBS and added growth factors serves multiple functions: providing nutrients, maintaining stemness, inducing differentiation, and enabling expansion, replacing the multi-functional role of feeder cells
Data Source
AI summary
The present invention is related generally to embryonic-like stem cells isolated from adult human peripheral blood, designated herein as peripheral blood-stem cells (PB-SC), which display the characteristics of embryonic stem cells and hematopoietic cells. These cells have the capability of proliferation and are able to differentiate to other types of cells. These cells are, therefore, suitable for use in stem cell-based therapies, particularly autologous stem cell therapies, for the treatment of various diseases such as neurodegenerative diseases, autoimmune diseases, diabetes, spinal cord damage, multiple sclerosis, cardiovascular disease, stroke and birth defects.